About us
Currently available European estimates, show that PPD prevalence ranges from 4% to 38%, carrying several consequences for women, newborns-infants, and family systems, representing a socioeconomic burden to society.
Riseup-PPD aims at filling gaps in PPD research, practice and social awareness by developing updated reviews fostering research efforts on the standardization of diagnostic criteria, the development of adequate screening tools and cost-effectiveness evaluation of prevention and treatment programs. Additionally, the Action seeks to bridge multidisciplinary knowledge on the determinants of depressive symptoms in the peripartum period, and the mechanisms of action and change. Finally, Riseup-PPD also aims at building a shared database providing research teams with large quality-controlled datasets.
Riseup-PPD aims at filling gaps in PPD research, practice and social awareness by developing updated reviews fostering research efforts on the standardization of diagnostic criteria, the development of adequate screening tools and cost-effectiveness evaluation of prevention and treatment programs. Additionally, the Action seeks to bridge multidisciplinary knowledge on the determinants of depressive symptoms in the peripartum period, and the mechanisms of action and change. Finally, Riseup-PPD also aims at building a shared database providing research teams with large quality-controlled datasets.
Riseup-PPD (COST Action CA18138) is funded by the Horizon 2020 Framework Programme of the European Union through the European Cooperation in Science and Technology (COST). COST is a funding agency for research and innovation networks. COST actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
|